Business
WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024
WuXi XDC Cayman Inc. (the "WuXi XDC" or the "Group", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, is pleased to announce its annual results for 2024 (the "Reporting Period").
About this update from Wuxi Xdc Cayman, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Revenue increased by 90.8% YoY to RMB 4,052 million ","length":51,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross profit grew by 121.6% YoY to RMB 1,240 million, with its margin of 30.6%, a 4.3 percentage points increase compared to that of 2023","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"Net profit surged by 277.2% YoY to RMB 1,070 million, with its margin of 26.4%, a 13.0 percentage points increase compared to that of 2023","length":138,"tagName":"p"}]},{"val":[{"type":"text","content":"The total global customer base expanded to 499, adding 154 new customers in 2024","length":80,"tagName":"p"}]},{"val":[{"type":"text","content":"The total number of iCMC projects reached 194, adding 53 new iCMC projects to the portfolio","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"The total backlog grew to US$991 million, representing a 71.3% YoY growth","length":73,"tagName":"p"}]},{"val":[{"type":"text","content":"Launched a new production line, BCM2 Line 2, at the Wuxi site, further increased manufacturing capacities ","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"The construction of Singapore commercial site is progressing smoothly and well on track for operation commencement by the end of 2025","length":133,"tagName":"p"}]},{"val":[{"type":"text","content":"Winner of the "Best CDMO" Award consecutively in 2023 and 2024","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Continue to invest in frontier technology, solidifying the Group's competitiveness and leadership position","length":110,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":990,"olType":false},{"type":"text","content":"SHANGHAI, March 24, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. (the "WuXi XDC" or the "Group", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, is pleased to announce its annual results for 2024 (the "Reporting Period").","length":350,"tagName":"p"},{"type":"text","content":"Dr. Jimmy Li, CEO of WuXi XDC, stated, "The year 2024 has been another year of exceptional growth and remarkable achievements for us, even as we navigated a dynamic macro environment. Our strong performances reflect the rel...